C. R. Bard, Inc. Second Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component C. R. Bard, Inc. (NYSE:BCR) will unveil its latest earnings on Monday, July 18, 2011. C.R. Bard, Inc. designs, manufactures and sells diagnostic, medical, surgical and patient care devices.

C. R. Bard, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of $1.57 per share, a rise of 12.9% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.59. Between one and three months ago, the average estimate moved down and dropped from $1.58 during the last month. For the year, analysts are projecting net income of $6.41 per share, a rise of 14.5% from last year.

Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 5 cents, reporting profit of $1.51 per share against a mean estimate of net income of $1.46 per share.

Savvy Investing Tip: Our CHEAT SHEET investing framework recommends only stocks with two straight quarters of earnings growth. Learn More >>

Wall St. Revenue Expectations: On average, analysts predict $728.9 million in revenue this quarter, a rise of 8.2% from the year ago quarter. Analysts are forecasting total revenue of $2.93 billion for the year, a rise of 7.7% from last year’s revenue of $2.72 billion.

Analyst Ratings: Analysts seem relatively indifferent about C. R. Bard with 14 of 19 analysts surveyed maintaining a hold rating.

Key Stats:

Revenue has risen the past four quarters. Revenue increased 7.6% to $700.3 million in first quarter. The figure rose 5.9% in the fourth quarter of the last fiscal year from the year earlier, climbed 6.5% in the third quarter of the last fiscal year from the year-ago quarter and 7.9% in the second quarter of the last fiscal year.

The company has now seen net income rise in two straight quarters. In the first quarter, net income rose 9.1% from the year earlier. In the fourth quarter of the last fiscal year, the figure rose 28.6%.

Competitors to Watch: Teleflex Incorporated (NYSE:TFX), Covidien plc (NYSE:COV), Boston Scientific Corp. (NYSE:BSX), Merit Medical Systems, Inc. (NASDAQ:MMSI), AngioDynamics, Inc. (NASDAQ:ANGO), Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI), Theragenics Corporation (NYSE:TGX), Rochester Medical Corp. (NASDAQ:ROCM), CONMED Corporation (NASDAQ:CNMD), and Becton, Dickinson and Co. (NYSE:BDX).

Stock Price Performance: During April 14, 2011 to July 12, 2011, the stock price had risen $11.20 (11.1%) from $101.07 to $112.27. The stock price saw one of its best stretches over the last year between November 10, 2010, and November 17, 2010, when shares rose for six-straight days, rising 2.3% (+$1.92) over that span. Shares have been on a negative streak of late, closing down every day between July 11, 2011 and July 12, 2011. Shares are up $20.84 (+22.8%) year to date.

(Source: Xignite Financials)

Get Actionable Investing Insights: Check Out Wall St. Cheat Sheet’s newest Feature Trades of the Month!